内源性逆转录病毒来源的新抗原实现胶质母细胞瘤的个性化癌症疫苗策略

Introduction/Rationale: Glioblastoma is refractory to immunotherapy because of low mutational burden and paucity of canonical neoantigens. Aberrant expression of endogenous retroviral elements (ERVs), reactivated genomic remnants of ancient viral insertions, may provide an alternative, tumor-specific antigen source suitable for personalized vaccines incorporating both mutation- and ERV-derived epitopes. Methods: Tumor and matched normal tissues from 25 glioblastoma patients, including 18 long-term survivors (>5 years) and 7 short-term survivors (<18 months), underwent whole-genome and RNA sequencing. Candidate antigens were predicted using AI-based pipelines to identify mutation-derived neoantigens and to derive ERV-encoded epitopes. AI-identified tumor-specific vaccine candidates were ranked by expression, predicted MHC class I and II binding affinity, clonality, and immunogenicity. Top candidates informed design of a personalized DNA vaccine encoding ten patient-specific sequences with a CCL19 molecular adjuvant to enhance dendritic-cell recruitment. ERV-derived immunogenicity was assessed by IFN-gamma ELISpot using peripheral blood mononuclear cells (PBMCs) from HLA-typed healthy donors stimulated with synthetic peptides. Results: High-quality mutation-derived neoantigens were rare (median 3 per patient). In contrast, all tumors expressed abundant, patient-specific ERV transcripts independent of mutation load, with several loci showing clonal, tumor-restricted expression. ERV-derived peptides demonstrated strong predicted MHC class I and II binding, and 22 of 25 tumors contained ERV epitopes meeting criteria for vaccine inclusion. These mapped predominantly to HERV-K and HERV-W families and frequently overlapped interferon-stimulated genomic loci, consistent with innate immune or epigenetic activation. Functional validation studies have demonstrated significant ERV-specific IFN-gamma responses in certain HLA allele contexts, highlighting the potential for allele-specific immunogenicity. While T-cell responses were observed in selected donor profiles, others exhibited more restricted reactivity despite validated positive controls, underscoring the importance of genetic context in immune response profiles. Additionally, our ongoing analyses are focused on elucidating ERV expression signatures that may correlate with sustained immune control by comparing long-term and short-term survivor cohorts, with the aim of identifying key immunological patterns associated with favorable outcomes. Conclusion: ERVs are consistently expressed, immunogenic, and largely tumor-restricted in glioblastoma, providing a scalable antigen source that may overcome limitations imposed by low mutational burden. These findings offer a strong proof-of-concept for personalized DNA vaccines incorporating ERV-derived neoantigens.